Susquehanna Fundamental Investments’s Kalaris Therapeutics KLRS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$127K	Sell	816 -176	-18%	-$35.1K	﹤0.01%	1437
2021 Q4	$295K	Sell	992 -44	-4%	-$20.4K	0.01%	1123
2021 Q3	$597K	Buy	+1,036	New	+$480K	0.01%	1115
2021 Q1	–	Sell	-1,016	Closed	-$898K	–	1638
2020 Q4	$898K	Sell	1,016 -217	-18%	-$167K	0.02%	902
2020 Q3	$780K	Buy	+1,233	New	+$842K	0.02%	729

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Susquehanna Fundamental Investments's KLRS Position: Q1 2022 in Review

Susquehanna Fundamental Investments reduced its Kalaris Therapeutics (KLRS) stake by 18% in Q1 2022, selling an estimated $35.1K and leaving 816 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1437.

Susquehanna Fundamental Investments first reported a position in KLRS in Q3 2020 and has held it in 5 quarters since. The position peaked at $898K in Q4 2020. 84 funds tracked by Wall St. Rank hold KLRS as of Q1 2022.

Susquehanna Fundamental Investments held 816 shares of Kalaris Therapeutics worth $127K as of Q1 2022.
Susquehanna Fundamental Investments sold 176 Kalaris Therapeutics shares in Q1 2022, an estimated $35.1K.
Kalaris Therapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1437 holding.
Susquehanna Fundamental Investments first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 5 quarters since.
Susquehanna Fundamental Investments's Kalaris Therapeutics position peaked at $898K in Q4 2020.
84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.